Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL.

Br J Cancer. 2010 Mar 16;102(6):981-6. doi: 10.1038/sj.bjc.6605580.

2.

Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.

Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Sato A, Koizumi W, Mizunuma N, Takiuchi H.

Jpn J Clin Oncol. 2010 Oct;40(10):913-20. doi: 10.1093/jjco/hyq069.

3.

Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.

Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, Shaked A, Reddy R, Olthoff K.

Cancer. 2011 Jul 15;117(14):3187-92. doi: 10.1002/cncr.25889.

4.

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.

Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I.

J Clin Oncol. 2009 Nov 20;27(33):5499-505. doi: 10.1200/JCO.2008.21.5384.

PMID:
19858399
5.

Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.

Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA.

Cancer. 2011 Sep 15;117(18):4125-31. doi: 10.1002/cncr.25992.

6.

A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.

Puthillath A, Mashtare T Jr, Wilding G, Khushalani N, Steinbrenner L, Ross ME, Romano K, Wisniewski M, Fakih MG.

Crit Rev Oncol Hematol. 2009 Sep;71(3):242-8. doi: 10.1016/j.critrevonc.2008.10.012.

PMID:
19081732
7.

Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.

He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC.

World J Gastroenterol. 2013 Jul 28;19(28):4552-8. doi: 10.3748/wjg.v19.i28.4552.

8.

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K.

J Clin Oncol. 2006 Apr 20;24(12):1898-903.

PMID:
16622265
9.

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.

Boige V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M; Fédération Francophone de Cancérologie Digestive..

Br J Cancer. 2007 Oct 8;97(7):862-7.

10.

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.

Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC.

Ann Oncol. 2010 Feb;21(2):269-74. doi: 10.1093/annonc/mdp512.

11.

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.

Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D.

Cancer Chemother Pharmacol. 2013 Jan;71(1):257-64. doi: 10.1007/s00280-012-2004-x.

PMID:
23100174
12.

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK.

Invest New Drugs. 2011 Apr;29(2):366-73. doi: 10.1007/s10637-009-9363-0.

PMID:
19997960
13.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ.

J Clin Oncol. 2010 Jul 1;28(19):3191-8. doi: 10.1200/JCO.2009.27.7723.

PMID:
20516443
14.

Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.

Michalaki V, Fotiou S, Gennatas S, Gennatas C.

Anticancer Res. 2010 Jul;30(7):3051-4.

PMID:
20683054
15.

Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.

Ang SF, Tan SH, Toh HC, Poon DY, Ong SY, Foo KF, Choo SP.

Am J Clin Oncol. 2012 Jun;35(3):222-7. doi: 10.1097/COC.0b013e31820dbf56.

PMID:
21378539
16.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group..

Eur J Cancer. 2014 Dec;50(18):3077-88.

PMID:
25459393
17.

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.

Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK.

Br J Cancer. 2008 Jan 29;98(2):316-22. doi: 10.1038/sj.bjc.6604186.

18.

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.

Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, Bolaños M, Gil M, Llombart A, Castro-Carpeño J, González-Barón M.

Br J Cancer. 2010 May 11;102(10):1468-73. doi: 10.1038/sj.bjc.6605663.

19.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E.

J Clin Oncol. 2008 Jul 20;26(21):3523-9. doi: 10.1200/JCO.2007.15.4138. Erratum in: J Clin Oncol. 2008 Oct 1;26(28): 4697.

PMID:
18640933
20.

Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.

Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C, Cheng AL.

Oncology. 2013;85(1):44-52. doi: 10.1159/000350841.

PMID:
23838576
Items per page

Supplemental Content

Support Center